These data suggest a model in which SMARCA4 plays a dominant role in regulating cyclin D1 expression and drug response to CDK4/6 inhibitors in NSCLC cells, but SMARCA2 becomes limiting when SMARCA4 is absent. This evidence concerns the gene SMARCA2 and non-small cell lung carcinoma.